======= SARS =======
== Gene Information ==
* **Official Symbol**: SARS1
* **Official Name**: seryl-tRNA synthetase 1
* **Aliases and Previous Symbols**: N/A
* **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=6301|6301]]
* **UniProt**: [[https://www.uniprot.org/uniprot/P49591|P49591]]
* **Interactions**: [[https://thebiogrid.org/search.php?search=SARS&organism=9606|BioGRID]]
* **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20SARS|Open PubMed]]
* **OMIM**: [[https://omim.org/entry/607529|Open OMIM]]
== Function Summary ==
* **Entrez Summary**: N/A
* **UniProt Summary**: Catalyzes the attachment of serine to tRNA(Ser) in a two-step reaction: serine is first activated by ATP to form Ser- AMP and then transferred to the acceptor end of tRNA(Ser) (PubMed:22353712, PubMed:24095058, PubMed:9431993, PubMed:26433229, PubMed:28236339). Is probably also able to aminoacylate tRNA(Sec) with serine, to form the misacylated tRNA L-seryl-tRNA(Sec), which will be further converted into selenocysteinyl-tRNA(Sec) (PubMed:9431993, PubMed:26433229, PubMed:28236339). In the nucleus, binds to the VEGFA core promoter and prevents MYC binding and transcriptional activation by MYC (PubMed:24940000). Recruits SIRT2 to the VEGFA promoter, promoting deacetylation of histone H4 at 'Lys-16' (H4K16). Thereby, inhibits the production of VEGFA and sprouting angiogenesis mediated by VEGFA (PubMed:19423848, PubMed:19423847, PubMed:24940000). {ECO:0000269|PubMed:19423847, ECO:0000269|PubMed:19423848, ECO:0000269|PubMed:22353712, ECO:0000269|PubMed:24095058, ECO:0000269|PubMed:24940000, ECO:0000269|PubMed:26433229, ECO:0000269|PubMed:28236339, ECO:0000269|PubMed:9431993}.
|tRNA-synt 2b|
|Seryl tRNA N|
|seryl-tRNA aminoacylation|
|serine-tRNA ligase activity|
|negative regulation of vascular endothelial growth factor production|
|selenocysteinyl-tRNA(Sec) biosynthetic process|
|selenocysteine metabolic process|
|regulation of vascular endothelial growth factor production|
|serine family amino acid metabolic process|
|tRNA aminoacylation for protein translation|
|tRNA aminoacylation|
|amino acid activation|
|negative regulation of angiogenesis|
|negative regulation of blood vessel morphogenesis|
|negative regulation of vasculature development|
|tRNA processing|
|tRNA metabolic process|
|alpha-amino acid metabolic process|
|negative regulation of cytokine production|
|regulation of angiogenesis|
|cellular amino acid metabolic process|
|regulation of vasculature development|
|translation|
|ncRNA processing|
|peptide biosynthetic process|
|ncRNA metabolic process|
|RNA polymerase II proximal promoter sequence-specific DNA binding|
|amide biosynthetic process|
|peptide metabolic process|
|RNA biosynthetic process|
|regulation of cytokine production|
|cellular amide metabolic process|
|negative regulation of transcription by RNA polymerase II|
|RNA processing|
|protein homodimerization activity|
|carboxylic acid metabolic process|
|negative regulation of developmental process|
|oxoacid metabolic process|
|organic acid metabolic process|
|regulation of anatomical structure morphogenesis|
|nucleobase-containing compound biosynthetic process|
|heterocycle biosynthetic process|
|aromatic compound biosynthetic process|
|negative regulation of transcription, DNA-templated|
|negative regulation of multicellular organismal process|
|negative regulation of nucleic acid-templated transcription|
|negative regulation of RNA biosynthetic process|
|organic cyclic compound biosynthetic process|
|negative regulation of RNA metabolic process|
|negative regulation of cellular macromolecule biosynthetic process|
|RNA binding|
|organonitrogen compound biosynthetic process|
|negative regulation of nucleobase-containing compound metabolic process|
|negative regulation of macromolecule biosynthetic process|
|ATP binding|
|negative regulation of cellular biosynthetic process|
|negative regulation of biosynthetic process|
|cellular nitrogen compound biosynthetic process|
|RNA metabolic process|
|cellular macromolecule biosynthetic process|
|negative regulation of gene expression|
|small molecule metabolic process|
|macromolecule biosynthetic process|
|gene expression|
\\
=== CRISPR Data ===
^Screen^Score^
|[[:results:exp497|Lead acetate 2000μM R08 exp497]]|-2.83|
|[[:results:exp467|CAY10603 0.55μM R08 exp467]]|-2.73|
|[[:results:exp407|Thapsigargin 0.005μM R07 exp407]]|-2.6|
|[[:results:exp434|Vemurafenib 6.6μM R08 exp434]]|-2.49|
|[[:results:exp65|Mubritinib 0.2μM R02 exp65]]|-2.4|
|[[:results:exp330|5-Azacytidine 2μM R07 exp330]]|-2.28|
|[[:results:exp133|MKC9989 10μM R03 exp133]]|-2.24|
|[[:results:exp93|DABN racemic mixture R03 exp93]]|-2.21|
|[[:results:exp520|Rucaparib 6.5μM R08 exp520]]|-2.18|
|[[:results:exp357|Dorsomorphin 5μM R07 exp357]]|-2.17|
|[[:results:exp473|Cincreasin 100μM R08 exp473]]|-2.15|
|[[:results:exp505|ML-792 0.2μM R08 exp505]]|-2.11|
|[[:results:exp352|Dexamethasone 0.006 to 0.015μM on day4 R07 exp352]]|-2.07|
|[[:results:exp45|Docetaxel 0.002μM R01 exp45]]|-2.05|
|[[:results:exp485|GSK626616 14μM R08 exp485]]|-2.02|
|[[:results:exp431|Rotenone 0.07μM R08 exp431]]|-2|
|[[:results:exp476|Dihydrosphingosine 8μM R08 exp476]]|-1.98|
|[[:results:exp512|Olaparib 4μM R08 exp512]]|-1.88|
|[[:results:exp142|OICR-9429 10μM R03 exp142]]|-1.72|
|[[:results:exp412|THZ531 0.11 to 0.125 to 0.35μM on day4 then day6 R07 exp412]]|-1.71|
|[[:results:exp7|Bortezomib 0.05μM R00 exp7]]|1.73|
|[[:results:exp472|CI-1040 9.5μM R08 exp472]]|1.78|
|[[:results:exp401|SNS-032 25μM R07 exp401]]|1.78|
|[[:results:exp531|THZ1 0.06μM R08 exp531]]|1.8|
|[[:results:exp526|Sulforaphane 9μM R08 exp526 no dilution day6]]|1.82|
|[[:results:exp456|Benzoate 20000μM R08 exp456]]|2.06|
|[[:results:exp451|Atovaquone 15μM R08 exp451]]|2.09|
|[[:results:exp493|IL-3 9ng/ml R08 exp493]]|2.11|
|[[:results:exp19|Etoposide 1μM R00 exp19]]|2.13|
|[[:results:exp465|Cannabidiol 13μM R08 exp465]]|2.74|
|[[:results:exp469|CFI-400945 25μM R08 exp469]]|2.81|
|[[:results:exp514|Phorbol-12-myristate-13-acetate 0.57μM R08 exp514]]|2.81|
^Gene^Correlation^
|[[:human genes:h:hars|HARS]]|0.497|
Global Fraction of Cell Lines Where Essential: 739/739
^Tissue^Fraction Of Cell Lines Where Essential^
|1290807.0|1/1|
|909776.0|1/1|
|bile duct|28/28|
|blood|28/28|
|bone|26/26|
|breast|33/33|
|central nervous system|56/56|
|cervix|4/4|
|colorectal|17/17|
|esophagus|13/13|
|fibroblast|1/1|
|gastric|16/16|
|kidney|21/21|
|liver|20/20|
|lung|75/75|
|lymphocyte|16/16|
|ovary|26/26|
|pancreas|24/24|
|peripheral nervous system|16/16|
|plasma cell|15/15|
|prostate|1/1|
|skin|24/24|
|soft tissue|9/9|
|thyroid|2/2|
|upper aerodigestive|22/22|
|urinary tract|29/29|
|uterus|5/5|
== Essentiality in NALM6 ==
* **Essentiality Rank**: 170
* **Expression level (log2 read counts)**: 7.15
{{:chemogenomics:nalm6 dist.png?nolink |}}